Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
138 Breast Cancer Trials near Glendale, AZ
Power is an online platform that helps thousands of Breast Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerMRT-2359 for Solid Tumors
Scottsdale, Arizona
This trial tests a new drug called MRT-2359 that breaks down a protein in cancer cells. It targets patients with certain types of previously treated cancers. The drug aims to destroy a protein crucial for cancer cell survival, potentially stopping or slowing the cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Malabsorption, CNS Involvement, Cardiac Disease, Others
Must Be Taking:Fulvestrant, Enzalutamide
174 Participants Needed
CLSP-1025 for Cancer
Scottsdale, Arizona
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Li-Fraumeni Syndrome, Active Infection, Others
90 Participants Needed
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
Scottsdale, Arizona
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Brain Metastasis, Active Infection, Others
Must Not Be Taking:Chronic Steroids
733 Participants Needed
STX-001 + Keytruda for Solid Tumors
Scottsdale, Arizona
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Organ Transplant, HIV, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
108 Participants Needed
Gadolinium-Based Contrast Media Effects on Motor and Cognitive Functioning
Scottsdale, Arizona
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth.
In this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years.
The study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Neurological, Psychiatric, Renal, Alcoholic Cirrhosis, Others
Must Not Be Taking:Neuro-cognitive Drugs
2076 Participants Needed
ORIC-114 for Solid Tumors
Phoenix, Arizona
This trial tests ORIC-114, a new oral medicine for advanced cancers. It targets proteins that help cancer grow, including in the brain, and is for patients who need new treatment options.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:EGFR T790M Mutation, ILD, Others
350 Participants Needed
IMC-F106C Combinations for Solid Cancers
Scottsdale, Arizona
This trial tests IMC-F106C, a treatment that helps the immune system target and kill cancer cells in adults with advanced cancers. It guides immune cells to attack cancer cells more effectively.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Metastasis, Lung Disease, Others
Must Not Be Taking:Antibiotics, Vaccines
727 Participants Needed
LY3410738 for Solid Tumors
Phoenix, Arizona
This trial is testing a new oral drug called LY3410738 in patients with advanced solid tumors that have specific genetic mutations. The drug works by blocking abnormal enzymes to potentially stop or slow cancer growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Active CNS Metastases, Uncontrolled Cardiac Disease, Others
Must Not Be Taking:Strong CYP3A4 Inhibitors, P-gp Inhibitors
200 Participants Needed
Proton Beam vs X-ray Radiation Therapy for Breast Cancer
Scottsdale, Arizona
This phase III trial compares the rate of complications of x-ray therapy versus proton beam radiation therapy after breast conserving surgery or mastectomy in treating patients with breast cancer. X-ray therapy is a form of radiation therapy that uses high-energy radiation from x-rays to kill tumor cells and shrink tumors. Proton beam radiation therapy is a type of radiation therapy that uses high-energy beams to treat tumors. It is not yet known what level of complications x-ray therapy or proton beam radiation therapy have in treating patients with breast cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Female
Key Eligibility Criteria
Disqualifiers:Severe Illnesses, Active Lupus, Scleroderma, Others
146 Participants Needed
Sacituzumab Govitecan for Breast Cancer
Chandler, Arizona
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Active Second Malignancy, Serious Infection, Hepatitis B/C, Others
Must Be Taking:Antiretroviral Therapy
654 Participants Needed
Trastuzumab Deruxtecan for Breast Cancer
Scottsdale, Arizona
This trial is testing a new drug called trastuzumab deruxtecan for patients with advanced breast cancer that hasn't responded to other treatments. The drug works by specifically targeting and killing cancer cells. The study aims to see if this drug helps patients live longer or improves their quality of life compared to other treatments. Trastuzumab deruxtecan has shown significant clinical benefits in treating advanced breast cancer and other similar tumors.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Lung Disease, Cardiovascular, CNS Metastases, Others
Must Be Taking:Endocrine Therapy
866 Participants Needed
Low-Dose Aspirin for Breast Cancer Prevention
Scottsdale, Arizona
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Breast Cancer, Other Cancer, Post-menopausal, Others
Must Not Be Taking:NSAIDs, Anticoagulants
100 Participants Needed
Abemaciclib for Triple Negative Breast Cancer
Scottsdale, Arizona
This trial studies how well abemaciclib works in patients with triple negative breast cancer that can be surgically removed but does not respond to chemotherapy. Abemaciclib is a pill that may help stop cancer cell growth by blocking certain enzymes. The trial includes patients who receive different treatments before surgery.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Active DVT/PE, Prior Radiation, Others
Must Not Be Taking:CDK 4/6 Inhibitors
200 Participants Needed
FASN Inhibitor + Trastuzumab for Breast Cancer
Scottsdale, Arizona
This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic). FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used in endocrine therapy either lower the amount of estrogen made by the body or blocks the use of estrogen by the tumor cells. This may help stop the growth of tumor cells that need estrogen to grow. Giving FASN inhibitor TVB-2640 and trastuzumab in combination with paclitaxel or endocrine therapy may help control the disease in patients with HER2 positive breast cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Brain Metastasis, Others
Must Be Taking:Anti-HER2 Therapy
19 Participants Needed
This trial tests a combination of a special vaccine, an immune booster, and a chemotherapy drug to prevent the return of triple negative breast cancer. It aims to help the immune system fight off cancer cells and use chemotherapy to kill any remaining ones.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Metastases, Autoimmune, Others
Must Not Be Taking:Corticosteroids, Immune-modulators, Her2-directed
280 Participants Needed
Radiation Therapy for Breast Cancer
Scottsdale, Arizona
This phase II trial studies how well hypofractionated radiation therapy works in treating participants with breast cancer before surgery. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Illnesses, Active Infection, Pregnancy, Others
25 Participants Needed
Personalized Adaptive Novel Agents for Breast Cancer
Scottsdale, Arizona
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Infections, Heart Failure, Angina, Others
Must Not Be Taking:Investigational Agents
5000 Participants Needed
LOXO-783 for Breast Cancer
Scottsdale, Arizona
This trial is testing LOXO-783, a new drug, to see if it is safe and effective for patients with breast cancer and other solid tumors that have a change in the PIK3CA gene. The drug works by blocking a gene that helps cancer cells grow.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Colorectal Cancer, Endometrial Cancers, Others
Must Be Taking:CDK4/6 Inhibitors
193 Participants Needed
Why Other Patients Applied
"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."
OF
Cholangiocarcinoma PatientAge: 54
"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."
EQ
Lung Cancer PatientAge: 70
"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."
FR
Lung Cancer PatientAge: 71
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."
UM
Pancreatic Cancer PatientAge: 48
Know someone looking for new options?
Spread the word